| H01626 | |
| H番号 | H01626 |
| 名称 | 閉塞性動脈硬化症 |
| 概要 | Arteriosclerosis obliterans (ASO) is one of the most common peripheral vascular diseases that causes ischemic symptoms of the lower limbs. Symptoms include discomfort, numbness, intermittent claudication, or even gangrene and ulceration. The risk factors of ASO include age, male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, chronic renal failure, and hyperhomocysteinemia. There are no definitive treatments for ASO. The efficacy of surgical treatment is not satisfactory, and medication is required to maintain the postoperative vascular patency. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Adsorption of low-density lipoprotein (LDL) has also been applied for the treatment of ASO. At present, the diagnosis of ASO depends on several clinical tests, such as angiography, estimations of ankle/brachial index (ABI), and pulse-wave velocity (PWV), as well as the measurement of circulating hs-CRP levels. However, these examinations can only be detectable when ASO already developed, and there was no predictable markers for ASO in its earlier stages. Recent studies have reported that some micro RNAs could be serum markers for early-stage ASO. |
| カテゴリ | 循環器系疾患 |
| ネットワーク | - |
| 病因遺伝子 | - |
| 病原体 | - |
| 環境要因 | - |
| 発癌物質 | - |
| 治療薬 | イソクスプリン塩酸塩 [DR:D01748] ヘプロニカート [DR:D01882] ニセリトロール [DR:D01754] ニコモール [DR:D01291] イコサペント酸エチル [DR:D01892] トコフェロールニコチン酸エステル [DR:D01530] アルガトロバン水和物 [DR:D00181] アルプロスタジル [DR:D00180] アルプロスタジル アルファデクス [DR:D02705] バトロキソビン [DR:D03352] ベペルミノゲンペルプラスミド [DR:D09839] |
| コメント | - |
| リンク | ICD-11: BD40 ICD-10: I70 MeSH: D001162 |
| 文献 | PMID:26632166 著者 Horie T, Kimura T, Ono K タイトル Emerging Novel Biomarkers for Arteriosclerosis Obliterans. 雑誌 J Atheroscler Thromb 23:171-2 (2016) DOI:10.5551/jat.ED028 PMID:23364237 著者 Ren S, Qian S, Wang W, Liu J, Liu P タイトル Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. 雑誌 Ann Thorac Cardiovasc Surg 19:30-4 (2013) DOI:10.5761/atcs.oa.12.02061 PMID:26370316 著者 He XM, Zheng YQ, Liu SZ, Liu Y, He YZ, Zhou XY タイトル Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. 雑誌 J Atheroscler Thromb 23:196-206 (2016) DOI:10.5551/jat.30775 PMID:26272221 著者 Mathur P, Ding Z, Saldeen T, Mehta JL タイトル Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease. 雑誌 Clin Cardiol 38:570-6 (2015) DOI:10.1002/clc.22422 PMID:23749750 著者 Arai T タイトル Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. 雑誌 Adv Ther 30:528-40 (2013) DOI:10.1007/s12325-013-0030-7 PMID:22142554 著者 Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G タイトル A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. 雑誌 Health Technol Assess 15:1-210 (2011) DOI:10.3310/hta15400 PMID:12886046 著者 Nakamura T, Kawagoe Y, Matsuda T, Takahashi Y, Sekizuka K, Ebihara I, Koide H タイトル Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. 雑誌 Kidney Blood Press Res 26:185-91 (2003) DOI:10.1159/000071884 |